News Release 12-129
Sophisticated technique for delivering multiple cancer treatments may solve frustrating hurdle for combined drug therapies
This material is available primarily for archival purposes. Telephone numbers or other contact information may be out of date; please see current contact information at media contacts.
This illustration depicts the nanolipogel, developed at Yale University with NSF support, administering its immunotherapy cargo. The light-blue spheres within the blood vessels and the cutaway sphere in the foreground, are the nanolipogels (NLGs). As the NLGs break down, they release IL-2 (the green specks), which helps recruit and activate a body's immune response (the purple, sphere-like cells). The tiny, bright blue spheres are the additional treatment, a cancer drug that inhibits TGF-beta (one of the cancer's defense chemicals).
Credit: Nicolle Rager Fuller, NSF
Download the high-resolution JPG version of the image. (1.4 MB)
Use your mouse to right-click (Mac users may need to Ctrl-click) the link above and choose the option that will save the file or target to your computer.
Yale University engineering professor Tarek Fahmy joined NSF to explain a novel, nanoscale, drug-delivery system that bundles powerful anti-cancer medicines into a single, treatment. The new approach solves several problems that hinder current drug delivery systems and has now proven effective in animal models.
Credit: National Science Foundation